<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823457</url>
  </required_header>
  <id_info>
    <org_study_id>53635</org_study_id>
    <nct_id>NCT02823457</nct_id>
  </id_info>
  <brief_title>VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C</brief_title>
  <acronym>VBMI SUD/HCV</acronym>
  <official_title>Evaluating Values-based Motivational Interviewing to Increase Treatment Completion With Fixed Dose Combination MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders and Treatment-naïve Genotype 1 Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.V. (Sonny) Montgomery VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>G.V. (Sonny) Montgomery VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study implement a values-based motivational interviewing (VBMI) intervention to promote
      treatment completion with fixed dose combination (FDC) MK-5172/MK-8742 x 12 weeks among 30
      Veterans with substance use disorder (SUD) and treatment naïve genotype 1 chronic hepatitis
      C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a prospective study of 30 Veterans with treatment-naive
      genotype 1 chronic hepatitis C infection admitted to the Substance Abuse Residential
      Rehabilitation Treatment Program (SARRTP) at the G.V. (Sonny) Montgomery VA Medical Center.
      Enrolled veterans will be treated MK-5172/MI-8742 while receiving a 12 week values based
      motivational intervention to promote completion of HCV treatment. MK-5172/MK-8742 will be
      prescribed in accordance with the package insert.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment completion</measure>
    <time_frame>12 weeks after initiation treatment</time_frame>
    <description>Number of participants who complete 12 weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders</condition>
  <arm_group>
    <arm_group_label>VBMI intervention group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive a 12 week VBMI intervention to promote treatment completion</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>VBMI</intervention_name>
    <description>12 week values based motivational interviewing intervention with a licensed psychologist</description>
    <arm_group_label>VBMI intervention group</arm_group_label>
    <other_name>Values Based Motivational Interviewing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Identified as having treatment-naïve genotype 1 chronic HCV infection; Veterans who
             are genotype 1a must have baseline NS5a resistance testing

          2. Current resident of the SARRTP program

          3. Willing to initiate treatment with FDC MK-5172/MK-8742 during SARRTP and up to 30
             days post-discharge.

          4. Willing to attend coordinated HCV treatment clinic visits and substance abuse
             aftercare visits every 2 weeks upon SARRTP discharge

        Exclusion Criteria:

          1. Contraindications for therapy with FDC MK-5172/MK-8742

          2. Unable to provide written informed consent

          3. Hepatocellular carcinoma or other medical condition precluding HCV treatment

          4. Acute HCV infection

          5. Prior treatment for chronic HCV

          6. History of decompensated cirrhosis

          7. Platelet count &lt; 75 K/cmm and/or albumin &lt; 3 grams/dL

          8. Females and male sex partners of females who are pregnant, nursing and/or unwilling
             to use contraception

          9. Patients infected with genotype 1a who have not undergone baseline NS5a resistance
             testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Burton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G.V. (Sonny) Montgomery VAMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Burton, MD</last_name>
    <phone>6013623371</phone>
    <email>mary.burton2@va.gov</email>
  </overall_contact>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 12, 2016</lastchanged_date>
  <firstreceived_date>July 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G.V. (Sonny) Montgomery VA Medical Center</investigator_affiliation>
    <investigator_full_name>Mary Jane Burton</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
